

Datasheet: MCA890F BATCH NUMBER 150146

Description:	MOUSE ANTI HUMAN CYTOKERATIN 14:FITC
Specificity:	CYTOKERATIN 14
Format:	FITC
Product Type:	Monoclonal Antibody
Clone:	LL002
Isotype:	IgG3
Quantity:	0.1 mg

Product Details

Applications	derived from testing w communications from	ithin our laboratories, the originators. Pleas al protocol recommer	he following application peer-reviewed publica re refer to references in ndations, please visit <u>w</u>	tions or personal dicated for further
		Yes No	Not Determined	Suggested Dilution
	Flow Cytometry (1)	•		Neat - 1/10
	Immunofluorescence	•		
	a guide only. It is reco system using appropri (1) Membrane perme	mmended that the us ate negative/positive abilisation is require	er titrates the antibody controls.	. Bio-Rad recommends
Target Species	Human			
Species Cross Reactivity	reactivity is derived fro	ty and working condition testing within our l	ions may vary between aboratories, peer-revie ors. Please refer to refe	wed publications or
Product Form	Purified IgG conjugate	ed to Fluorescein Isoth	niocyanate Isomer 1 (F	ITC) - liquid
Max Ex/Em	Fluorophore FITC	Excitation Max (nm) 490	Emission Max (nm) 525	
Preparation	Purified IgG prepared	by affinity chromatog	raphy on Protein G froi	m tissue culture

	supernatant
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃) 1% Bovine Serum Albumin
Approx. Protein Concentrations	IgG concentration 0.1mg/ml
Immunogen	Last 15 C-terminal residues of human cytokeratin 14 conjugated to thyroglobulin.
External Database Links	UniProt: <u>P02533</u> <u>Related reagents</u> Entrez Gene: <u>3861</u> KRT14 <u>Related reagents</u>
RRID	AB_872024
Specificity	Mouse anti Human Cytokeratin 14 antibody, clone LL002 recognizes cytokeratin 14, a type I intermediate filament, expressed by stratifying epithelial cells and can be used to distinguish these cell types from simple epithelial cells, which do not express cytokeratin 14. Mouse anti cytokeratin 14, clone LL002 has been reported to be suitable for use in Western blotting (<u>Alam <i>et al.</i> 2011</u>)
Flow Cytometry	Use 10ul of the suggested working dilution to label 1×10^6 cells in 100ul.
References	 Purkis, P.E. <i>et al.</i> (1990) Antibody markers of basal cells in complex epithelia. <u>J Cell</u> <u>Sci. 97 (Pt 1): 39-50.</u> Lane, E.B. & Alexander, C.M. (1990) Use of keratin antibodies in tumor diagnosis. <u>Semin Cancer Biol. 1 (3): 165-79.</u> Wetzels, R.H. <i>et al.</i> (1989) Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. <u>Am J Pathol. 134 (3):</u> <u>571-9.</u> Moll, R. <i>et al.</i> (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. <u>Cell. 31 (1): 11-24.</u>

of the lactating mammary gland of the African elephant (*Loxodonta africana*, Proboscidea) <u>Zoomorphology 123:155-67</u>

9. Alam H *et al.* (2011) Loss of keratins 8 and 18 leads to alterations in α 6 β 4-integrinmediated signalling and decreased neoplastic progression in an oral-tumour-derived cell line. <u>J Cell Sci. 124 (Pt 12): 2096-106.</u>

10. Clark, S.E. *et al.* (2011) Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. <u>Br J Cancer. 104: 120-7.</u>

11. Caceres, S. *et al.* (2015) Establishment and Characterization of a New Cell Line of Canine Inflammatory Mammary Cancer: IPC-366. <u>PLoS One. 10 (3): e0122277.</u>

12. Takahashi, C. *et al.* (2010) Newly established cell lines from mouse oral epithelium regenerate teeth when combined with dental mesenchyme. <u>In Vitro Cell Dev Biol Anim.</u> <u>46: 457-68.</u>

13. Faustino, A.M. & Dias Pereira, P. (2007) A salivary malignant myoepithelioma in a dog. <u>Vet J. 173 (1): 223-6.</u>

14. Collins, A.T. *et al*et al. (2005) Prospective identification of tumorigenic prostate cancer stem cells. <u>Cancer Res. 65: 10946-51.</u>

15. Varley, C.L. *et al.* (2004) Activation of peroxisome proliferator-activated receptor-gamma reverses squamous metaplasia and induces transitional differentiation in normal human urothelial cells. <u>Am J Pathol. 164: 1789-98.</u>

16. Abdeen, S.K. *et al.* (2011) Wwox inactivation enhances mammary tumorigenesis. <u>Oncogene. 30: 3900-6.</u>

17. Matos, A.J. *et al.* (2006) Detection of lymph node micrometastases in malignant mammary tumours in dogs by cytokeratin immunostaining. <u>Vet Rec. 158: 626-30.</u>

18. Turner, A. *et al.* (2011) Transplantation of autologous differentiated urothelium in an experimental model of composite cystoplasty. <u>Eur Urol. 59: 447-54.</u>

19. Munz, B. *et al.* (1999) Overexpression of activin A in the skin of transgenic mice reveals new activities of activin in epidermal morphogenesis, dermal fibrosis and wound repair. <u>EMBO J. 18: 5205-15.</u>

20. Mwase, M. *et al.* (2013) Cutaneous Squamous Cell Carcinoma presenting as a Wound with Discharging Sinus Tracts in a Wild African Lion (*Panthera leo*). J Comp Pathol. pii: <u>S0021-9975(13)00106-0.</u>

21. Honda, K. & Tomooka, Y. (2016) Nerve-independent and ectopically additional induction of taste buds in organ culture of fetal tongues. *<u>In Vitro Cell Dev Biol Anim. 52</u>* (9): 911-9.

22. Hustler, A. *et al.* (2018) Differential transcription factor expression by human epithelial cells of buccal and urothelial derivation. <u>Exp Cell Res. 369 (2): 284-294.</u>

23. Ogihara, K. & Madarame, H. (2020) Pancreatic adenosquamous carcinoma with invasion to the spleen in a cat. <u>J Vet Med Sci. 82 (9): 1395-9.</u>

Storage	 Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. This product is photosensitive and should be protected from light. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch

Informati	on <u>h</u>	laterial Safety Da <u>ttps://www.bio-ra</u> 0041	le at:		
Regulato	ry F	For research purposes only			
Relate	d Products				
Recomm	nended Usefu	I Reagents			
HUMAN S	ERM (BUF09) EROBLOCK (BU EROBLOCK (BU				
	Tel: +1 800 265 7376		de Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50
Iorth & South	Fax: +1 919 878 375				

Printed on 18 Jan 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint